Frontiers in Pharmacology

SGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis

Figure 1 from Frontiers in Pharmacology — Figure 1. He et al.

Meta-analysis of randomised trialsInterventions

The paper

Zongze He, Xu Wang, Li Zhang, Xiangmei Chen

Chinese PLA General Hospital

Frontiers in Pharmacology, 24 Sep 2026

doi.org/10.3389/fphar.2026.1882227 PubMed 42851802

Nature Medicine4 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk